Feature | Cath Lab | September 12, 2017

Cardiovascular Research Foundation Appointed Juan Granada as New President, CEO

Distinguished cardiologist takes the helm of key interventional cardiology organization, sponsor of TCT

Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).


September 12, 2017 – The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). Granada was also appointed to CRF’s Board of Directors. A renowned leader in cardiology, he joined CRF in 2007 and served as executive director and chief innovation officer at the CRF Skirball Center for Innovation. He is also an assistant professor of medicine at Columbia University College of Physicians and Surgeons. 

Granada also has served as a member of the Editorial Board for Diagnostic and Interventional Cardiology (DAIC) magazine since 2010.

“Juan’s proven leadership skills, along with his expertise across preclinical, clinical, and educational initiatives will help CRF strengthen and expand its role in the development of innovative new technologies and therapies that will benefit people with heart disease worldwide,” said Eric B. Woldenberg, Esq., chairman of the CRF Board of Directors and a senior partner at Pryor Cashman LLP.

“Since its inception, CRF has played a major role in the rapid progress that has been made in interventional cardiology by establishing the safe use of new technologies and therapies for heart disease,” Granada said. “I am eager to take on this new role and work with my distinguished colleagues to ignite the next wave of innovation that will help doctors save and improve the quality of their patients’ lives.”

“CRF has grown due to a special blend of passion, creativity, and productivity, and Juan embodies our innovative culture,” said Martin B. Leon, M.D., founder and chairman emeritus of CRF and its co-director, medical research and education. “With his unique combination of advanced interventional skills, entrepreneurial spirit, and business insight, he has the visionary capacity to foresee new opportunities. Importantly, Juan is a caring and thoughtful people person who will catalyze communication and collaboration both inside and outside the organization.”

“Juan’s professionalism, creativity and ‘can do’ mindset make him an exceptional individual for this position,” added Gregg W. Stone, M.D., CRF’s co-director of medical research and education. “His knowledge of interventional cardiovascular medicine from bench to bedside coupled with extensive expertise in medical innovation will propel CRF to new levels of achievement in research and education.”

Granada is one of the world’s foremost investigators in the translational validation of novel cardiovascular therapies. He has helped develop and successfully validate several endovascular imaging and device technologies. He received his medical degree from the Institute of Health Sciences in Medellin, Colombia and finished his cardiovascular disease and interventional cardiology fellowships at Baylor College of Medicine in Houston, Texas.  

 

Video and Article Interviews With Dr. Juan Granada:

VIDEO: Bioresorbable Stent Failure Modes, Technique, Patient Selection and Future Development

VIDEO: Transcatheter Mitral Valve Technology, Anatomical Challenges

Advances and Future Directions for Transcatheter Valves

VIDEO: Transcatheter Mitral Valve Therapies in Development — TVT 2015

VIDEO: The Evolution of TAVR Technology — TVT 2015

Transcatheter Mitral Valve Replacement Devices in Development

Drug-eluting Balloons Enter the U.S. Market

Advances in Intravascular Imaging

 

For more information: www.crf.org


Related Content

Feature | Cardiovascular Business | By Merilee Kern, MBA

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

Home November 09, 2022
Home
News | Cardiovascular Business

November 1, 2022 — Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has ...

Home November 01, 2022
Home
Feature | Cardiovascular Business

November 1, 2022 — Johnson & Johnson and Abiomed, a world leader in breakthrough heart, lung and kidney support ...

Home November 01, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional ...

Home November 01, 2022
Home
News | Cardiovascular Business

October 31, 2022 — The Yale School of Medicine announced the passing of Robert W. Berliner Professor Emeritus of ...

Home October 31, 2022
Home
News | Cardiovascular Business

October 24, 2022 — Asher Kimchi, MD, clinical chief of Cardiology, vice-clinical chief of the Department of Medicine ...

Home October 24, 2022
Home
News | Cardiovascular Business

October 20, 2022 — Atlas Healthcare Partners – which specializes in developing and managing ambulatory surgery centers ...

Home October 20, 2022
Home
News | Cardiovascular Business

October 19, 2022 — Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named ...

Home October 19, 2022
Home
News | Cardiovascular Business

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home October 12, 2022
Home
News | Cardiovascular Business

October 6, 2022 – OpSens Inc., a Quebec-based medical device cardiology-focused company, has announced that it has ...

Home October 06, 2022
Home
Subscribe Now